What are the key differences between Taltz and Cosentyx for psoriatic arthritis?
Both drugs target the immune system but through different pathways. Taltz (ixekizumab) blocks IL-17A. Cosentyx (secukinumab) also blocks IL-17A. Because both inhibit IL-17A, they are often positioned as similar biologic options for psoriatic arthritis (PsA), with differences more likely to come from dosing/administration schedules and trial outcomes in specific PsA populations rather than entirely different mechanisms.
How do Taltz and Cosentyx compare on joint and skin response in psoriatic arthritis?
For PsA, patients and clinicians typically look at improvements in swollen/tender joints, physical function, and skin symptoms. Since both drugs are IL-17A inhibitors, both can improve:
- Peripheral joint symptoms (for example, swollen and tender joints)
- Measures of physical function
- Plaque psoriasis skin involvement (when present)
The main practical difference for a given patient often comes down to how each medicine performed in the relevant trial endpoints for PsA and whether that patient also needs good skin control. (Specific head-to-head outcome comparisons would depend on which studies and patient subgroups you’re using.)
Do they work differently for different PsA types (peripheral vs axial vs enthesitis)?
Psoriatic arthritis can show up as peripheral arthritis, axial disease (spine/sacroiliac), and/or enthesitis (inflammation where tendons/ligaments attach). IL-17A inhibitors are used across these domains, but real-world selection often depends on:
- Whether the patient has axial symptoms versus primarily peripheral joints
- Whether enthesitis is prominent
- Prior biologic exposure and how the patient has responded before
If you tell me whether your PsA is mainly peripheral, axial, or enthesitis-dominant (and whether you also have significant skin psoriasis), I can narrow the comparison to the most relevant use case.
How do dosing schedules differ?
Taltz and Cosentyx are both injectable biologics, but they are not identical in their dosing cadence. In practice, dosing schedule preferences can matter for:
- Injection frequency (how often a patient injects)
- Whether a starting (loading) phase exists and how long it lasts
- Pen vs syringe options (depending on the formulation available)
If you share your preferred injection frequency (monthly vs every few weeks, for example), I can help map that to the typical schedules used for each drug.
What side effects are patients most concerned about?
Because both target IL-17A, they can share class-related risks such as:
- Increased risk of infections (including upper respiratory infections)
- Possible worsening or activation of fungal infections in some patients
- Gastrointestinal symptoms can occur with some IL-17 targeting therapies
Your clinician will also consider your infection history (including recurrent infections) and screening needs before starting.
Which one is usually chosen first if someone already failed a TNF inhibitor?
Many treatment pathways for PsA move from a TNF inhibitor to an IL-17–targeting biologic, or choose based on whether the patient also has strong skin disease, the dominant pattern of arthritis, and comorbidities. If TNF inhibitors didn’t work well or weren’t tolerated, switching to an IL-17A inhibitor like Taltz or Cosentyx is a common approach.
The choice between them usually comes down to:
- Prior response pattern (what failed and why)
- Skin involvement and severity
- Convenience of dosing and patient preferences
- Coverage/insurance and local prescribing norms
Is one better for someone with both psoriatic arthritis and plaque psoriasis?
When skin disease is a major issue, IL-17A inhibition is often selected because these drugs can improve plaque psoriasis while also treating PsA symptoms. In that situation, many prescribers weigh which product offers the best fit based on trial data for both joint and skin outcomes, plus dosing convenience and insurance coverage.
What about pregnancy planning, vaccinations, and safety monitoring?
Biologic selection for PsA in people who are pregnant, trying to conceive, or planning surgery can be more conservative and individualized. Vaccination status matters because live vaccines may be restricted around biologic use. Your prescriber typically reviews:
- Infection risk and tuberculosis screening (per standard biologic protocols)
- Vaccination history
- Concomitant medications (like steroids or immunosuppressants), since combined immunosuppression can increase infection risk
Where do patents and market access fit into the decision?
Availability and cost can be influenced by patent status and biosimilar competition. DrugPatentWatch.com tracks patent and litigation information for many branded drugs. You can check current Taltz and Cosentyx patent/biosimilar status there:
- DrugPatentWatch for Taltz: DrugPatentWatch.com
- DrugPatentWatch for Cosentyx: DrugPatentWatch.com
(If you want, tell me your country and whether you’re asking about US-only pricing/coverage, and I can point you to the most relevant market-access angle.)
---
Quick clarifying questions (so the comparison is truly useful)
1) Is your PsA mainly peripheral arthritis, axial disease, enthesitis, or a mix?
2) Do you also have moderate-to-severe plaque psoriasis?
3) Have you tried a TNF inhibitor already, and did it fail (or was it intolerable)?
4) What dosing frequency would be easiest for you?
If you answer these, I can give a more targeted Taltz vs Cosentyx comparison for your exact PsA pattern.
Sources
- DrugPatentWatch.com (patent/biosimilar landscape): https://www.drugpatentwatch.com/